Mark A. Kay - 18 Jun 2021 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role: Director
Signature: /s/ Jonathan Quick, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 18 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 21 Jun 2021, 16:39:46 UTC
Previous filing: 14 Jun 2021
Next filing: 21 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LOGC	Stock Option (right to buy)	Award	$0	+5,000		$0.000000	5,000	18 Jun 2021	Common Stock	5,000	$4.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan in relation to the Reporting Person's service on the Issuer's Scientific Advisory Board. The options will vest over two years: 50% of the options will vest on the first anniversary of the grant date with the remaining 50% vesting on the second anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date.

Content

The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan in relation to the Reporting Person's service on the Issuer's Scientific Advisory Board. The options will vest over two years: 50% of the options will vest on the first anniversary of the grant date with the remaining 50% vesting on the second anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date.